Research graph
References from Safety and tolerability of Evusheld in patients with CVID: The Mayo Clinic experience. Local targets link to admitted publications; unresolved targets remain external evidence.
Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency
10.1016/j.jaip.2021.11.030 · 2022 · External reference
COVID-19-related health outcomes in people with primary immunodeficiency: a systematic review
10.1016/j.clim.2022.109097 · 2022 · External reference
Coronavirus disease 2019 in patients with inborn errors of immunity: an international study
10.1016/j.jaci.2020.09.010 · 2021 · External reference
Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19
10.1001/jama.2021.24931 · 2022 · External reference
The arrival of SARS-CoV-2-neutralizing antibodies in a currently available commercial immunoglobulin
10.1016/j.jaci.2022.03.026 · 2022 · External reference
